Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H15O7.Cl |
Molecular Weight | 366.75 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].COC1=CC(=CC(OC)=C1O)C2=[O+]C3=CC(O)=CC(O)=C3C=C2O
InChI
InChIKey=KQIKOUUKQBTQBE-UHFFFAOYSA-N
InChI=1S/C17H14O7.ClH/c1-22-14-3-8(4-15(23-2)16(14)21)17-12(20)7-10-11(19)5-9(18)6-13(10)24-17;/h3-7H,1-2H3,(H3-,18,19,20,21);1H
Malvidin is a polyphenolic anthocyanin. Anthocyanins are flavonoids widely distributed in fruits and vegetables. Malvidin exhibits antiproliferative, antioxidant and anti-inflammatory bioactivities. It is able to inhibit cGMP-specific phosphodiesterase-5. Malvidin exhibited bimodal activities serving as breast cancer resistance protein (BCRP) substrate at low concentrations and, at higher concentrations, as BCRP inhibitor.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26417697
Curator's Comment: Malvidin is detectable in the piglet brain after oral administration of bilberry extract containing anthocyanins including malvidin.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006954 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24333549 |
|||
Target ID: CHEMBL1827 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15769121 |
24.9 µM [IC50] | ||
Target ID: GO:0006915 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15964118 |
|||
Target ID: GO:0008283 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15964118 |
|||
Target ID: CHEMBL5393 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19922539 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Antioxidant activity of anthocyanins and their aglycons. | 2003 Jan 29 |
|
In vitro inhibition of human cGMP-specific phosphodiesterase-5 by polyphenols from red grapes. | 2005 Mar 23 |
|
Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. | 2009 Dec |
|
Inhibitory effect of Malvidin on TNF-α-induced inflammatory response in endothelial cells. | 2014 Jan 15 |
|
Malvidin's Effects on Rat Pial Microvascular Permeability Changes Due to Hypoperfusion and Reperfusion Injury. | 2016 |
|
Malvidin Protects WI-38 Human Fibroblast Cells Against Stress-induced Premature Senescence. | 2016 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27445688
rats: i.v. malvidin, 9 or 18 mg/kg b.w.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16598815
At a concentration of 5 microM of malvidin a significant decrease of phosphorylated ERK1 and ERK2 (ERK, extracellular regulated kinase) in HT29 cells was observed. The release of cells, synchronised in the G(2)/M-phase of the cell cycle by nocodazole treatment, was effectively blocked in the presence of 1 microM malvidin.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C68444
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C68447
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY | NCIT | ||
|
GL5KGZ4D8U
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY | |||
|
211-403-8
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY | |||
|
DTXSID00982857
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY | |||
|
C065861
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY | |||
|
6674
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY | |||
|
Malvidin
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY | |||
|
69512
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY | |||
|
94526
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY | |||
|
144781
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY | |||
|
m7049
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
643-84-5
Created by
admin on Fri Dec 15 17:50:29 GMT 2023 , Edited by admin on Fri Dec 15 17:50:29 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD